We examined the mechanisms involved in the cardiovascular and renal response to prolonged infusion of atrial natriuretic factor (ANF) in patients with chronic heart failure. ANF infusion was titrated to produce a 30% decrease in pulmonary capillary wedge pressure or a 20% increase in cardiac output, and this dose (average, 75±4 ng/kg/min) was then administered for 20 hours. The short-term response to ANF included significant reductions in central filling pressures, increases in cardiac output, modest increases in diuresis and glomerular filtration rates, significant reduction in plasma aldosterone levels, and a 3.6-fold increase in plasma cyclic GMP levels. During prolonged infusion, plasma cGMP levels and cardiac output gradually returned to baseline. Similarly, the initially increased diuretic effects were completely abolished during prolonged ANF infusion, although plasma a-hANF levels remained consistently elevated above baseline values (control, 198±38; titration, 2,760±f596; 20 hours, 3,499±+659 pg/ml). Four hours after beginning the ANF infusion, marked increases in hematocrit levels were noted (42.5±1.0%o versus 45.3±1.4%, control and infusion, respectively, p <0.05); during this time, no change in total plasma protein concentration occurred, indicating extravascular shift of fluid and plasma proteins. No evidence was noted for activation of vasoconstrictor hormones during prolonged ANF infusion, although mean arterial pressure was significantly reduced throughout the infusion period. Plasma pro-ANF (31-67) levels, determined as a marker for endogenous ANF secretion, were significantly suppressed as were the reductions of central filling pressures. After ANF discontinuation, heart rate and pulmonary capillary wedge pressure increased significantly above baseline values without evidence for sympathetic stimulation. We conclude that 1) prolonged infusion of ANF causes only transient increases in plasma cGMP levels but a sustained reduction of the cardiac release of ANF and that 2) the beneficial hemodynamic effects of ANF, that is, unloading of the ventricles, may be associated with or, in part, may be secondary to a shift of plasma constituents into the extravascular space. The latter may limit the therapeutic potential of ANF for long-term treatment. (Circulation 1991;83:191-201) 
failure, a disease characterized by chronic fluid overload and edema formation. Therefore, the present study was designed to determine the cardiovascular and renal efficacy of ANF during a 20-hour infusion period in patients with moderate-to-severe chronic heart failure. In an attempt to elucidate the mechanisms involved in this response, we measured neurohumoral parameters, such as norepinephrine, epinephrine, aldosterone, plasma renin activity, and plasma cGMP levels. In addition, measurements of the pro-ANF fragment provided a means to characterize the endogenous secretion of ANF during administration of the biologically active 99-126 peptide. [18] [19] [20] Relative changes within fluid compartments were assessed by serial determination of hematocrit levels and total plasma protein concentrations.
Methods Patients
Ten patients with chronic congestive heart failure were studied after giving written, informed consent. The experimental protocol was approved by the ethical committee of the University of Freiburg. The group comprised nine men and one woman, aged 45-67 years, who had an ejection fraction (determined by left ventricular angiography) of 30% or less (Table 1) . Nine patients were in New York Heart Association (NYHA) functional class III, and one patient was in NYHA class II. Eight patients had ischemic cardiomyopathy, and two patients had idiopathic dilated cardiomyopathy. Patients with recent history of myocardial infarction, valvular heart disease, or recent acute decompensation were excluded. Four days before the study, therapy with angiotensin converting enzyme inhibitors was discontinued, and 2 days before the study, therapy with short-acting vasodilators and diuretics was stopped (Table 1) . Anticoagulants, antiarrhythmic agents, and digitalis were continued throughout the study.
Study Protocol
At 8:00 AM on the day of the study, a 7F SwanGanz thermodilution catheter was placed percutaneously from the basilic vein in the arm and was advanced into the pulmonary artery under fluoroscopic guidance. A peripheral line was inserted for infusion of a-hANF (99-126) (Bissendorf, Wedemark, FRG), and a bladder catheter was placed for urine sampling. Thereafter, a light breakfast was provided (one cup of tea and one sandwich). Additional light meals were provided immediately after hemodynamic measurements were obtained at 2:00 PM and 6:00 PM. Urine produced in an initial 60-minute equilibration period was discarded. At 10:00 AM, a 3.5 -hour urine collection period was started, and it served as the control phase. Hemodynamic stability (<10% variation) was ensured by two consecutive measurements performed at 30-minute intervals (beginning at 1:30 PM). After baseline measurements were obtained (Bi and B2; see Figure 1 ), dose titration was started by infusing ANF at a rate of 20 ng/kg/min. The infusion rate was doubled every 15 minutes to achieve a 30% reduction in pulmonary capillary wedge pressure or a 20% increase in cardiac index. After achieving the desired hemodynamic response, the infusion rate (average, 75±4 ng/kg/ min) was maintained for 20 hours. Hemodynamic measurements were repeated 4, 8, 12, 16 , and 20 hours after starting the ANF infusion. Thereafter, the drug was discontinued, and repeated hemodynamic measurements were obtained 4 hours later. Blood samples were drawn from the right atrium for analyzing plasma a-hANF (99-126) and pro-hANF (31-67) levels, plasma cGMP concentrations, hematocrit levels, plasma protein levels, electrolyte levels, aldosterone levels, catecholamine levels, and plasma renin activity as indicated in Figure 1 During the titration period, pulmonary capillary wedge, right atrial, and mean pulmonary artery pressures fell significantly, whereas mean arterial pressure and heart rate did not change (Figure 2 ).
Cardiac index increased and systemic vascular resistance decreased significantly at the highest titration dose. During prolonged infusion, mean arterial pressure declined significantly 4 hours after ANF initiation and remained reduced during long-term ANF infusion. The fall in mean arterial pressure was mainly due to a decrease in systemic vascular resistance because cardiac index returned to baseline at the 4-hour time point (Figure 3 ). The reduction in central filling pressures was maintained throughout the infusion period ( Figure 2 ). The heart rate showed no significant changes despite the considerable decline in mean arterial pressure (Figure 3 ).
Plasma ANF, Pro-hANF (31-67), and Plasma cGMP Levels ANF plasma concentrations increased 17-fold during the titration period ( Figure 4) . Four were not significantly different from control values after discontinuation of ANF.
After ANF discontinuation, plasma ANF levels declined to 329±100 pg/ml, and pro-hANF (31-67) levels increased to 3,240±689 pg/ml, but plasma norepinephrine levels and plasma renin activity did not change. Hemodynamic, Hornonal, and Renal Effects The hemodynamic effect of ANF in response to the highest titration dose included decreases in central filling pressures, systemic vascular resistance, and an increase in cardiac index, which is in keeping with previous studies.12 Four hours after ANF initiation, however, cardiac index returned to baseline. The return of cardiac index to control values may be, in part, due to a further fall in cardiac preload induced by the noticeable plasma contraction observed within the first 4 hours of ANF infusion. In contrast to the evanescent effects of ANF on cardiac output, the reductions in central filling pressure, mean arterial pressure, and systemic vascular resistance are maintained throughout the ANF infusion period.
During prolonged infusion, no counterregulatory changes were observed that involved the renin-angiotensin-aldosterone system and the sympathetic nervous system despite considerable reductions in mean arterial pressure. This may be explained either by an inhibitory action of ANF on hormone release8-11 or by the consequence of an overall improvement in systemic hemodynamics. Webster et a127 reported ) levels were nine times higher than the levels in healthy controls, indicating an increased secretory activity of the overloaded heart.43 During short-term unloading of the heart during the titration period, N-terminal peptide concentrations remained unchanged, although central filling pressures declined significantly, probably reflecting the slower rate of pro-hANF (31-67) degradation compared with that of a-hANF. Alternatively, a slowly changing constitutive release of pro-hANF from the ventricle44 contributed to the circulating pro-hANF (31-67) levels in our patients. In contrast, 4 hours after the start of ANF administration, levels of the pro-hANF declined significantly (Figure 4 ) and remained suppressed as did the reduction in central filling pressure. Therefore, the present data indicate that the N-terminal fragment (31-67) may be a marker for long-term changes of endogenous ANF secretion during infusion of the biologically active peptide.
Relative Changes Between Fluid Compartments
The observed hematocrit changes during ANF infusion indicate that ANF caused a shift of fluid into the extravascular space similar to recent reports.1 This effect has been attributed to an ANF-induced venoconstriction,17,45 with subsequent increase in capillary hydraulic pressure together with an increase in capillary hydraulic conductivity,46 favoring net filtration of fluid into the extravascular compartment. Interestingly, hematocrit levels increased only in patients with filling pressures of more than 22 mm Hg, indicating that the degree of fluid extravasation in response to short-term ANF administration may depend on preexisting interstitial fluid pressure. Four hours after the start of ANF infusion, a marked increase in the hematocrit level was noted in every patient, despite fluid replacement, suggesting a shift of fluid into the extravascular space. This increase in the hematocrit level was accompanied by a decreased rather than increased plasma protein concentration (Table 3) , suggesting a transcapillary shift of proteins into the extravascular space because renal protein excretion rate remained unaltered. During long-term infusion, plasma protein concentrations declined further and' were accompanied by a return of the hematocrit level to baseline. Obviously, a time-dependent dissociation of fluid and plasma protein shift emerged, which cannot readily be explained by the present data. However, a similar pattern of hematocrit changes was observed during ANF long-term infusion in the conscious sheep.47 Moreover, the protein extravasation occurring during ANF infusion is consistent with recent experimental findings.48 '49 Taken together, ANF seems to alter three important variables of Starling's law of the capillaries, favoring extravasation of plasma constituents into the third space. Conceivably, edema formation in congestive heart failure and other conditions associated with abnormally high plasma ANF levels may be, in part, attributed to ANF.
Limitations of the Study
The lack of a controlled study design raises the possibility that the observed changes in hemodynamics and hormonal parameters may, in part, represent diurnal variations. Because we considered a placebocontrolled design unethical in this population of severely ill patients, a 4-hour run-in period was performed, yielding stable baseline conditions. Furthermore, ambulatory monitoring of pulmonary artery pressure in patients with chronic heart failure revealed that, during the night, central filling pressures increase rather than decrease in most patients.50 Therefore, the reduction in filling pressure during the night in our patient group can be attributed to the administration of ANF.
Clinical Implications
Prolonged administration of ANF results in attenuation of renal and, in part, of hemodynamic effects and facilities protein shift into the extravascular space, which may limit the therapeutic potential. Of emphasis, high doses of ANF were necessary for achieving a defined hemodynamic effect. Although hemodynamic unloading has been achieved by ANF, the reduction in circulating volume occurred mainly by extravasation rather than renal excretion. It remains to be elucidated whether intermittent administration of ANF or only modest increases in plasma ANF (e.g., inhibition of ANF degradation) can avoid these adverse effects and, therefore, exert beneficial effects on hemodynamics, neurohumoral constrictor forces, and renal function in patients with chronic heart failure.
